Document Detail

Beneficial effects of almitrine bismesylate on pulmonary gas exchange in COPD.
MedLine Citation:
PMID:  6586439     Owner:  NLM     Status:  MEDLINE    
Almitrine bismesylate 100 mg orally was given to eight patients with severe chronic obstructive pulmonary disease (COPD). In five patients, gasometric, haemodynamic and lung mechanics parameters, and almitrine plasma levels were measured at baseline and every hour up to five hours after almitrine bismesylate intake. Maximal almitrine plasma levels were reached after 2 hours (89 +/- 41 ng/ml, mean +/- SEM) and persisted up to the fifth hour (68 +/- 25 ng/ml). Pulmonary vascular resistance increased significantly from baseline 433 +/- 120 to 503 +/- 124, p less than 0.05 at the second hour and to 509 +/- 119, p less than 0.05 at the fifth hour. Arterial oxygen saturation increased significantly from baseline 81.7 +/- 4.9% to 84.5 +/- 5.0, p less than 0.05 at the second hour and to 84.5 +/- 4.6, p less than 0.05 at the fifth hour. Venous admixture decreased significantly from baseline 35 +/- 9% to 30 +/- 9, p less than 0.05 at the second hour and to 28 +/- 9, p less than 0.01 at the fifth hour. Pulmonary artery mean pressure, cardiac output and minute ventilation did not change. The continuous distributions of ventilation-perfusion ratios (VA/Q), using the multiple inert gas elimination technique, were determined in six patients, at baseline and two hours after almitrine bismesylate intake. An improvement in VA/Q matching was observed after almitrine with a diversion of an average of 15 per cent of total blood flow from hypoxic units (VA/Q between 0.08 and 0.4) to normoxic units (VA/Q between 0.5 and 1.8).(ABSTRACT TRUNCATED AT 250 WORDS)
C Melot; R Naeije; R Hallemans; P Mols; P Lejeune
Related Documents :
9137229 - Characteristics of pulmonary artery pressure waveform for differential diagnosis of chr...
22062669 - Reduction of bacillus subtilis, bacillus stearothermophilus and streptococcus faecalis ...
6600739 - Pulmonary blood flow distribution measured by radionuclide-computed tomography.
3191759 - Reduction of pulmonary capillary blood volume following cold exposure in patients with ...
12462669 - Chronic oral sildenafil therapy in severe pulmonary artery hypertension.
14636929 - Echocardiographic determination of mean pulmonary artery pressure.
7867239 - Noninvasive evaluation of contractile state by left ventricular dp/dtmax divided by end...
18062519 - Attenuation of hypotension using phenylephrine during induction of anaesthesia with pro...
2369039 - Effect of helium concentration on experimental upper airway obstruction.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of respiratory diseases. Supplement     Volume:  126     ISSN:  0106-4347     ISO Abbreviation:  Eur J Respir Dis Suppl     Publication Date:  1983  
Date Detail:
Created Date:  1984-07-09     Completed Date:  1984-07-09     Revised Date:  2008-02-21    
Medline Journal Info:
Nlm Unique ID:  8010618     Medline TA:  Eur J Respir Dis Suppl     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  249-54     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Lung Diseases, Obstructive / drug therapy*
Middle Aged
Piperazines / therapeutic use*
Pulmonary Gas Exchange / drug effects*
Ventilation-Perfusion Ratio / drug effects
Reg. No./Substance:
0/Piperazines; 27469-53-0/Almitrine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacological properties of almitrine bismesylate.
Next Document:  Effects and handling of almitrine bismesylate in healthy subjects.